Rubius is advancing its new class of cellular medicines called Red Cell Therapeutics (RCTs) — red blood cells engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent, and allogeneic cellular therapies . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post A Ruby in the Rough: Rubius Transforms Red Blood Cells into Cellular Medicines appeared first on GEN – Genetic Engineering and Biotechnology News.
